PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France
Abstract
Authors
C. Chouaid L. Bensimon J. Tardu A. Millier R. Insinga A. Rai L. Levy-Bachelot P. Levy